tbuckley/cabot-search huggingface dataset:
Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC).
Authors: Lakhan Kashyap, Vijay Maruti Patil, Sachin Babanrao Dhumal, Vanita Noronha, Amit Joshi, Nandini Sharrel Menon, Kumar Prabhash
Journal: Journal of Clinical Oncology (2020)

e18550 Background: NACT regimen for patients with oral cavity scc is based on maximum tolerated doses (MTD). Combination of MTD and metronomic chemotherapy schedule will lead to initial debulking of tumor and subsequent inhibition of angiogenesis, this may produce synergistic effect and overcome the drug resistance of MTD schedule. We assessed the efficacy and safety of this combination as NACT in patients with technically unresectable oral cavity SCC. Methods: This is retrospective analysis of prospectively maintained data. Fourteen patients having technically unresectable oral cavity SCC received NACT with paclitaxel (175mg/m2) plus carboplatin (AUC5) 3 weekly (MTD schedule) and OMCT (methotrexate 9mg/m2 once a week, celecoxib 200mg twice daily and erlotinib 150mg once daily). Patient were assessed clinically and radiologically after minimum of two cycles for resectability. Radiological response was evaluated as per RECIST 1.1. We report response rate, resectability and tolerance of this NACT regimen. Results: Median age of the patients was 38 years. Twelve patients (85%) were male. Twelve (85%) and two (15%) patients had buccal mucosa and oral tongue primary respectively. AJCC 2017 stage IVA and IVB disease was present in 85% and 15% patients respectively. Reason for technical unresectabilty was skin edema above zygoma in five (36%), high infratemporal fossa involvement in five (36%), nodal encasement of major vessels in two (14%) and posterior extent of oral tongue tumor into oropharynx in two (14%) patients. Median number of NACT administered were three. The tumor of nine (64%) patients showed partial response and none of the patients had tumor progression. Tumor of nine patients (64%) were deemed resectable after NACT. Common grade 3/4 toxicities (CTCAE 5.0) were neutropenia in eight (57%), thrombocytopenia in three (21%), febrile neutropenia, hypokalemia and diarrhoea in two patients (14%) each. Conclusions: Paclitaxel and carboplatin along with OMCT is well tolerated and easily administered NACT regimen with high response rate and resectabilty in patients with technically unresectable oral cavity SCC.
急性阑尾炎致脐尿管炎一例
Authors: 丁学兵, 刘迎梅, 徐培强, 颜廷华, 杨加保
Journal: BMJ (2005)

患者男,40岁.因中下腹阵发性隐痛8 h入院,向下腹部放射,无发热,无尿频、尿急、尿痛,无恶心、呕吐、腹胀、腹泻.查体:痛苦貌,屈曲位.腹平坦,中下腹轻度肌紧张,局限性压痛、反跳痛,肠鸣音加快.结肠充气试验、闭孔内肌试验阳性,腰大肌试验阴性.血常规:白细胞计数13×109/L,中性粒细胞分类0.89.尿常规、X线腹部平片正常.腹部超声:泌尿系统未见异常,1条索状物在脐和膀胱间,直径1.5 cm,内无血流通过,不与膀胱相通。
Survey on methicillin-resistant staphylococccus aureus carrying status in health care workers
Authors: Yanping Li, Yi Chen, Fengli Song, Wei Shi, Jingzhi Chen, Xiuhua Ma
Journal: BMJ (2017)

Swabbing samples were routinely collected from health care workers (HCW) contacting newborns in Obstetrics Department of our hospital on every Wednesday during January to December 2015. Total 495 samples from nasal vestibule and 483 samples from hands of HCW were collected for bacterial culture. The carrying status of methicillin-resistant staphylococccus aureus (MRSA) was analyzed. The results showed that the average carrying rate of MRSA in the nasal vestibule was 8.1%(40/495) and that in hands was 5.0(24/483)(χ2=3.871, P<0.05). The MRSA detection rate of nasal vestibular samples in the second quarter was the highest [12.2%(17/139)], while that of hands samples was highest in the first quarter [15.3%(15/98)]. The study indicates that carrying rate of MRSA in health care workers contacting newborns of our hospital is high, and the training and monitoring should be strengthened among health workers to reduce the MRSA carrying rate.


Key words: 
Health care workers, neonatal nursing; Methicillin-resistant staphylococcus aureus; Bacteria carrying status
Genetic profiling and the response to RET inhibitors in RET fusion positive non-small cell lung cancer (NSCLC) identified by international genomic screening project (LC-SCRUM-Asia).
Authors: Kaname Nosaki, Shingo Matsumoto, Kiyotaka Yoh, Takaya Ikeda, Yuichiro Ohe, Masahiro Kodani, Noriko Yanagitani, Kazumi Nishino, Masato Shingyoji, Shinji Takeuchi, Yoshitaka Zenke, Hibiki Udagawa, Keisuke Kirita, Seiji Niho, Koichi Goto
Journal: Journal of Clinical Oncology (2020)

9557 Background: RET fusions are targetable oncogenic drivers in 1 – 2 % of NSCLC, yet no RET inhibitors are approved. Selective RET inhibitors, such as LOXO-292 and BLU-667, are currently in development. The impact of co-occurring mutation on outcome in RET-TKI therapy remains largely unknown. Methods: In an international genome screening project in Asia (LC-SCRUM-Asia), 161 cancer-related genes have been analyzed by a next-generation sequencing (NGS) system, Oncomine™ Comprehensive Assay. The therapeutic efficacy and survival of RET fusion+ NSCLC were evaluated using a large-scale clinicogenomic database in the LC-SCRUM-Japan. Results: From Feb 2013 to Dec 2019, a total of 7177 patients with non-squamous NSCLC were enrolled. RET fusion were detected in 167 patients (2.3 %). Median age was 61 years (range: 29 - 85), 60 % were female, 61 % were never-smokers, 99 % had adenocarcinoma, and 78 % had stage IIIB/IV disease. Based on our database, the median overall survival was 37 months. 62 patients received RET inhibitor therapy. RET fusions was identified by NGS assay (KIF5B-RET: 75, CCDC6-RET: 30, Others: 2) in 107 patients. Co-occurring genomic alterations were detected in 62 (58 %) patients, the median number of co-mutations was 1 (range 0 - 4). The most common co-occurring mutations in tumor involved TP53 (31; 29 %), STK11 (6; 6 %), CDKN2A (5; 5 %) and TSC2 (5; 5 %). In 23 patients treated with RET inhibitor (unapproved drugs), there was a strong association between co-occurring mutation and time to treatment discontinuation (TTD) in RET inhibitor therapy; HR 2.75 (95%CI 1.71 - 15.6, P = 0.0096). Conclusions: RET rearrangements continue to represent a rare but high unmet need disease. Co-occurring mutation was significantly associated with shorter TTD. Our data is the largest cohort of advanced-stage RET fusion+ NSCLC profiled by NGS to date. Co-occurring mutation should be evaluated in the development of novel targeted therapies for RET fusion+ NSCLC.
Survey of asthmatic knowledge among respiratory physicians in different grade hospitals of Gansu Province
Authors: Hairong Bao, Jie Yang, Chao Guo, Xiaoju Liu, Yi Zhang, Enli Tan
Journal: BMJ (2014)

To explore the asthmatic knowledge of physicians in different grade hospitals in Gansu Province. We designed a face-to-face questionnaire with 450 physicians. And 393 of them completed the survey. The percentage of physicians correctly understanding the mechanism of asthma, drug of choice in acute exacerbation of asthma, the first-line treatment of moderate or severe chronic persistent asthma, optimal route of administration of non-acute asthma attack and use of aerosol were 61.1%, 38.2%, 49.6%, 65.4% and 33.6% respectively. The percentage of them who believed that asthma could be completely and adequately controlled was 22.1% and 53.2% respectively. Only 30.8% physicians understood the meaning and usage of peak flow meter. The awareness of physicians at grade 3A hospitals was superior to that at 2A and 3B hospitals (P<0.05 or P<0.01).


Key words: 
Asthma; Questionnaire
Nonfatal, Fatal Overdoses Rising
Authors: Bridget M. Kuehn
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
被疑诊为心肌梗死的患者
Authors: 曾昭耆
Journal: BMJ (2006)

患者男,79岁,某部离休干部.2004年8月23日因心前区持续性疼痛2天就诊.自述疼痛特点为自深部向外拱动,血压140/70 mm Hg(18.6/9.3 kPa),心率64次/min,因自己怀疑为心肌梗死而来院急诊。
Transarterial infusion chemotherapy (TAI) combined with Sintilimab in locally advanced, potentially resectable hepatocellular carcinoma (HCC).
Authors: Li Xu, Yaojun Zhang, Xiaohui Wang, Mude Shi, Juncheng Wang, Yuhao Tang, Yizhen Fu, Zhongguo Zhou, Minshan Chen
Journal: Journal of Clinical Oncology (2020)

e16593 Background: Our previous studies showed that TAI with modified FOLFOX increased tumor response and resection rate compared with conventional TACE in advanced HCC. PD-1/PD-L1 inhibitors have been demonstrated promising value in HCC. This study aims to evaluate the efficacy and safety of FOLFOX-TAI combined with Sintilimab (a PD-1 inhibitor) in locally advanced, potentially resectable HCC. Methods: This prospective, nonrandomized controlled phase II study is recruiting 40 pts with locally advanced, potentially resectable HCC (localized to semi-liver with invasion to branch of the portal vein). Pts in the combined group receive repeated 3-week cycles of Sintilimab 200mg IV Day1 and TAI with FOLFOX Day2 (Oxaliplatin 130 mg/m 2 , Leucovorin 400 mg/m 2 , 5-FU 400 mg/m 2 and 5-FU 2400 mg/m 2 , next 46 hours). Pts in the control group only received TAI. Tumor assessment with RECIST 1.1 was performed every 2 cycles. The pts gained visible tumor shrinkage and opportunity for resection received surgical hepatectomy. Pts with stable disease (SD) or unconfirmed progression disease (PD) will receive repeated cycles until confirmed PD or intolerable toxicity, with max cycles of 8 for TAI and 16 for Sintilimab. The primary endpoint is progression or postoperative relapse free survival (PFS). Secondary endpoints include ORR, DCR, resection rate, OS, and safety. Results: As of Jan 10, 2020, 33 eligible pts were enrolled. All treatment related AEs were grade 1 or 2, including transaminase and bilirubin increase, nausea, hypoalbuminemia, rash, leucopenia, thrombopenia, and weight loss. No irAE and treatment related SAE was observed. Conclusions: TAI combined with Sintilimab attributed to high surgical conversion rate and good safety profile for locally advanced, potentially resectable HCC. Clinical trial information: NCT03869034 .
The relationship between leptin, leptin receptor, and FGFR1 in primary human breast tumors.
Authors: Wyatt Shoemaker, Shreya Paithankar, Vanessa Benham, Bin Chen, Jamie Bernard
Journal: Journal of Clinical Oncology (2020)

e13578 Background: General/overall obesity and visceral/central obesity are associated with increased breast cancer risk and poorer cancer outcomes; however, the precise etiology of these observations is not fully known. Our previous research suggests that adipose tissue-derived fibroblast growth factor 2 (FGF2) promotes malignant transformation of mammary epithelial cells through the activation of its primary receptor, fibroblast growth factor receptor 1 (FGFR1). Both FGF2 and leptin have been shown to be elevated in the serum in obesity (body mass index (BMI) &gt; 25kg/m 2 ). It is well established that elevated sera leptin promotes breast cancer through multiple mechanisms. Therefore, we hypothesized that tumors that express elevated FGFR1 and leptin receptor (LepR) may have a poorer prognosis in obese patients. Methods: Databases that house gene-sequenced breast cancer tumors and normal breast tissue were analyzed to discern relationships between gene copy number and mRNA levels of leptin, leptin receptor, FGFR1 and janus kinase 2 (Jak2), as Jak2 was shown to be a common downstream mediator of both FGFR1 and leptin receptor activation by Cytoscape network analysis. Furthermore, we tested the efficacy of Jak2 inhibitors for preventing mammary epithelial cell malignant transformation using our well-established models of adipose tissue-stimulated growth in soft agar. The anchorage-independent growth in soft agar is a surrogate marker for malignant transformation. Results: A much stronger significant relationship exists between FGFR1 mRNA and leptin mRNA in primary breast cancer (p = 3.17*10 −9 ) compared with normal breast epithelium (p = 0.0013). In primary breast tumors, gene copy number of FGFR1 positively correlates with leptin copy number (p = 8.956*10 −8 , r = 0.19). Moreover, two separate Jak2 inhibitors attenuated both leptin+FGF2-stimulated and mouse adipose tissue-stimulated MCF-10A cell transformation. Conclusions: Taken together, these results suggest that elevated sera FGF2 and leptin in obese patients may promote breast tumorigenesis in tumors that express elevated FGFR1 and LepR and that Jak2 inhibitors may be a novel therapeutic option for adiposity-driven breast cancers. Future work will examine the relationship between FGFR1/leptin receptor expression and survival and how these relationships are influenced by BMI status.
蓝橡皮疱性痣综合征一例
Authors: 梁海清, 王福胜, 赵秀明
Journal: BMJ (2007)

蓝橡皮疱性痣综合征(blue rubber-bleb nevus syndrome,BRBNS)是一种以皮肤和胃肠道表皮血管畸形伴发消化道出血和缺铁性贫血为特征的罕见疾病.病因不明,多为散发病例.我院于2006年12月诊断出1例,复习总结如下。
Comparison of quality of life in patients with resectable esophageal cancer after esophagectomy followed by gastric tube or whole stomach reconstruction
Authors: Zhen-bing You, Wei Guo, Wei-guo Zhu, Da-fu Xu, Jian Ji, Hong-jun Chu
Journal: BMJ (2010)

From June 2007 to June 2009, 133 patients underwent esophageal resection, among them 64 cases received esophageal reconstruction with narrow gastric tube (NGT) and 69 received esophageal reconstruction with whole stomach (WS).The postoperative quality of life (QOL) in 6 months of both groups was investigated.The study found that there were 3 cases in WS group having leakage, while no one in NGT group, the weight loss, regurgitation and chest-stomach syndrome in NGT group were superior to those in WS group, there were no statistical differences in activities of daily life, emotional functions, food intake, dysphagia between two groups.The study indicates that the quality of life in NGT group is superior to that in WS group.

Key words: 
Esophageal neoplasms;  Quality of life
关注心血管疾病患者的精神心理问题
Authors: 刘梅颜, 胡大一
Journal: BMJ (2007)

随着科技的进步和社会压力的增加,精神心理问题和心血管疾病已成为主要的公共卫生问题.据WHO报告[1],当今心理问题已成为世界的第四大疾患.有越来越多的证据表明,精神心理问题和心血管疾病可以互为因果,互相影响,共同导致患者预后恶化,二者的共病问题已成为最严重的健康问题之一。
循证医学精粹
Authors: 吴东, 陈嘉林
Journal: BMJ (2010)

一、经验危险,决定不易(experience is perilous and decision difficult) 这句话出自古希腊医学家希波克拉底(Hippocrates),原句是:Life is short,and art long;the crisis fleeting;experience perilous,and decision difficult(生命短暂,医术恒久,危机转瞬,经验危险,决定不易)。
Performance of cell-free tumor DNA testing for 101 clinical laboratories on College of American Pathologists proficiency tests.
Authors: Christina M Lockwood, Rhona J Souers, Patricia Vasalos, Tanja Kalicanin, Kelly Devereaux, Rondell P. Graham, M Hameed, Mark Routbort, Jonathan M Tsai, Jason Derek Merker, Neal Ian Lindeman, Joel T Moncur
Journal: Journal of Clinical Oncology (2020)

e13681 Background: Cell-free tumor DNA or circulating tumor DNA tests are increasingly used in clinical care to detect somatic mutations from solid tumors. However, data on laboratory performance characteristics using standardized samples is limited. Methods: Well-characterized reference materials were used for the College of American Pathologists (CAP) cell-free tumor DNA proficiency testing surveys, which consisted of stabilized DNA fragmented to simulate cell-free DNA in a synthetic plasma matrix. For the 2018A, 2018B, 2019A and 2019B surveys, laboratories tested for hotspot mutations (single and dinucleotide sequence changes) in EGFR, BRAF, KRAS, NRAS, and IDH1 at variant allele fractions ranging from 0.1% - 1.0%. As per CAP proficiency testing standards, results were scored according to the known mutation(s) engineered at designated variant allele fractions in each PT sample. Nine laboratories were excluded from analysis because they provided incomplete results. Statistical significance was calculated using a multivariate logistic regression model. Results: In 2018 and 2019, 101 laboratories submitted survey results for at least one proficiency testing mailing. There were 5088 total proficiency testing responses for EGFR, BRAF, KRAS, NRAS, and IDH1 mutations across 12 different samples. For the 3585 responses submitted for BRAF, KRAS, NRAS, and IDH1, sensitivity ranged from 94.6 – 100%, while specificity exceeded 99%. There were no significant differences in performance between analytical methodologies for BRAF, KRAS, NRAS, and IDH1 mutations. Performance characteristics for EGFR mutations among the 1503 responses showed a combined sensitivity of 87.1% and specificity of 98.7%. For laboratories detecting mutations in EGFR, next-generation sequencing methods exhibited a sensitivity (true positivity) of 95.7% while the sensitivity of non-NGS methods was lower at 81.7% ( P= 0.02). Conclusions: These findings demonstrate high sensitivity and specificity for clinical laboratories performing cell-free tumor DNA tests. For EGFR mutations, NGS outperformed non-NGS methods. These data suggest excellent overall agreement among laboratories performing clinical cell-free tumor DNA tests. Further investigation across variant allele fractions and additional variant types is warranted.
Current status of professional value and influencing factors among health workers in grass-roots medical institutions in Wenzhou city
Authors: Zhouhao Dai, Yingying Wang, Xiaoming Zhou, Hui Xie, Zhiyi Wang, Jie Weng, Lei Guo, Jianshi Chen, Yuqiang Gong
Journal: BMJ (2019)

Objective
To survey the current status of professional value among health workers in grass-roots medical institutions of Wenzhou city and to analyze the influencing factors.


Methods
A survey on professional value was conducted from October to December 2017 among health workers from 14 primary medical institutions in 4 urban districts of Wenzhou City selected by stratified random sampling method. The self-designed questionnaires were used for the survey. A total of 350 questionnaires were distributed and 331 were returned, of which 302 were valid. The status and influencing factors of professional value were analyzed.


Results
The overall score of professional value was (96.66±14.94). The univariate analysis showed that the professional value scores were associated with educational level (F=3.851), income(F= 2.660), professional title(F=8.030),position(F=11.658) and specialty (F=4.667) of the health workers(all P< 0.05). The multivariate analysis showed that the gender(male: OR=0.53, 95% CI:-1.077--0.192, P=0.005), educational level (high school and below: OR=3.06, 95% CI: 0.007-2.233, P=0.049), income (2 000-4 000 Yuan: OR=0.07, 95% CI:- 4.783--0.627, P=0.011), professional title (no title: OR=0.27, 95%CI: -2.397--0.232, P=0.017; Junior title: OR=0.31, 95%CI:-2.197--0.153), P=0.024; intermediate title: OR=0.23, 95% CI:-2.533--0.366, P=0.009),position (doctor: OR=0.13, 95% CI:-3.235--0.815, P=0.001; nurse: OR=0.20, 95% CI:-2.883--0.368, P=0.011; technician: OR=0.15, 95% CI:-3.076--0.723, P=0.002) were influencing factors of professional value(all P<0.05).


Conclusion
The professional values among health workers in Wenzhou grass-roots medical institutions are relatively low. The male gender, low educational level, low income, low professional title or no title and positions are influencing factors of professional value.


Key words: 
Community health services; Medical staff; Social value
Chronic diarrhea and intestinal flora imbalance
Authors: Qiong Wu
Journal: BMJ (2018)

慢性腹泻是一种临床常见症状，病因多且复杂。肠道菌群是人体肠道内携带的细菌群，其数量庞大，种类繁多，功能丰富。正常情况下，肠道菌群保持动态平衡，与宿主互利共生，维持宿主身体的健康。当这种平衡被打破时，将出现菌群失调，导致疾病发生，通常表现为腹泻。粪菌移植可快速、经济、相对安全地重建正常的肠道微生态环境。
Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC).
Authors: Philip Agop Philip, Joanne Xiu, Michael J. Hall, Andrew Eugene Hendifar, Emil Lou, Jimmy J. Hwang, Jun Gong, Moh'd M. Khushman, Davendra Sohal, A. Craig Lockhart, Benjamin Adam Weinberg, John Marshall, Axel Grothey, Anthony Frank Shields, Wolfgang Michael Korn
Journal: Journal of Clinical Oncology (2020)

4629 Background: Genomic profiling has identified KRAS mutations in 88-90% of PC. KRAS WT tumors represent a molecularly heterogeneous group that may harbor targetable alterations (TA). We studied KRAS WT PC using NextGen sequencing (NGS) and whole transcriptome sequencing (WTS) to characterize the molecular landscape of this unique group and to assess the prevalence of TA. Methods: A total of 1164 PC tumors were tested at Caris Life Sciences by NGS (592 genes), WTS (NovaSeq), IHC and fragment analysis. Comparison of KRAS WT vs. mutant (MT) was done by Fisher-Exact or Chi2 and was corrected for multiple tests. Results: The KRAS WT cohort included 144 tumors (12.4%). No differences were seen in gender (female: 46% in both WT &amp; MT) and age (median: 66 &amp; 67) compared to KRAS MT. In KRAS WT tumors, targetable fusions tested by WTS and pathogenic mutations by NGS were seen in 22% (32 of 144) and 52% (75 of 144) respectively; potentially targetable amplifications (amp) were seen in 5 additional tumors. No TA were seen in 22% of WT tumors. Key alterations are in Table. Alterations inducing MAPK activation, including BRAF, RAF1, NF1 and GNAS changes were seen in 38 (26%) tumors. Frequent alterations were seen in FGFR genes (11 tumors), MET (4, including 1 exon 14 skip), and ERBB receptor and ligands (10). Fusions in ALK, ROS1, RET and NOTCH1 were seen (8), largely exclusive of other drivers. Wnt, PI3K, chromatin remodeling (CR) and DDR changes were common and sometimes seen concurrent with other alterations. Compared to KRAS MT, no difference of PD-L1 or TMB-H was seen. BRAF, APC, PBRM1, CTNNB1 mutations, MDM2 amp, gene fusions and MSI-H/dMMR were all more frequent in KRAS WT tumors (corrected p &lt; 0.05). Conclusions: KRAS WT PC is enriched with TA (e.g., BRAF, ALK, ROS1, NRG1, MSI-H). The use of WTS in combination with NGS identifies activated molecular pathways in the majority of KRAS WT tumors. Based on our findings, comprehensive profiling of PC at the DNA and RNA level is recommended to provide patients with therapeutic opportunities beyond standard treatments. [Table: see text]
Disease management for type 2 diabetes
Authors: 刘军秀, 谢朝晖, 李星明, 黄建始
Journal: BMJ (2007)

目前,全世界糖尿病患者约有2.5亿,约95%为2型糖尿病.糖尿病的死因顺位不论在发达国家还是发展中国家均排在前列,在我国糖尿病占到死因顺位的第9位[1].目前我国有糖尿病患者400万,其中95%以上是2型糖尿病[2],发病年龄呈年轻化、患病率呈持续上升趋势.由于对糖尿病的知晓率低,使目前糖尿病总的患病情况处于低估状态,未能反映真实情况[3]。